What is atomoxetine used for
Pro Research Analysisby 
Searched over 200M research papers
Atomoxetine: Uses and Efficacy in Treating ADHD
Introduction to Atomoxetine for ADHD Treatment
Atomoxetine is a selective norepinephrine reuptake inhibitor (NRI) that has been extensively studied and approved for the treatment of attention-deficit/hyperactivity disorder (ADHD) in children, adolescents, and adults. Unlike traditional stimulant medications, atomoxetine offers a non-stimulant alternative for managing ADHD symptoms 28.
Mechanism of Action: Norepinephrine Reuptake Inhibition
Atomoxetine works by inhibiting the presynaptic norepinephrine transporter, which increases the levels of norepinephrine in the brain. This mechanism is thought to enhance noradrenergic function, particularly in the prefrontal cortex, which is crucial for attention and executive function 159.
Clinical Efficacy in Children and Adolescents
Symptom Reduction and Functional Improvement
Multiple studies have demonstrated that atomoxetine is effective in reducing core ADHD symptoms such as inattention, hyperactivity, and impulsivity. In a randomized, placebo-controlled study involving 297 children and adolescents, atomoxetine significantly improved ADHD symptoms and social and family functioning compared to placebo . Another comprehensive review of over a decade of research confirmed that atomoxetine is effective in various pediatric populations, showing initial responses within one week and more robust responses over three months .
Comparison with Other ADHD Medications
Atomoxetine has been found to be as effective as immediate-release methylphenidate but less effective than extended-release formulations like osmotically released methylphenidate and extended-release mixed amphetamine salts 89. This makes atomoxetine a viable option for patients who do not respond well to or cannot tolerate stimulant medications.
Safety and Tolerability
Common Adverse Effects
Atomoxetine is generally well tolerated, with common side effects including headache, abdominal pain, decreased appetite, vomiting, somnolence, and nausea. These adverse events are typically mild to moderate and transient 49.
Long-term Safety
Long-term safety data indicate that atomoxetine is associated with modest increases in heart rate and blood pressure, but these changes are not clinically significant for most patients. Additionally, any initial reductions in growth (height and weight) appear to normalize over time 49.
Special Populations: Autism Spectrum Disorder
Atomoxetine has also been studied in children with autism spectrum disorder (ASD) who exhibit ADHD symptoms. A systematic review and meta-analysis found that atomoxetine improved hyperactivity and inattention in this population, although the magnitude of the effect is uncertain and more research is needed .
Dosage and Administration
Atomoxetine can be administered as a single daily dose or split into two evenly divided doses. The recommended target dosage is 1.2 mg/kg/day for children and adolescents weighing 70 kg or less, and 80 mg/day for those weighing over 70 kg and adults 18.
Conclusion
Atomoxetine is a well-established, non-stimulant treatment option for ADHD that offers efficacy in reducing core symptoms and improving functional outcomes. It is particularly useful for patients who do not respond to or cannot tolerate stimulant medications. While generally well tolerated, clinicians should monitor for common side effects and consider long-term safety data when prescribing atomoxetine.
Sources and full results
Most relevant research papers on this topic
Atomoxetine: a selective noradrenaline reuptake inhibitor for the treatment of attention-deficit/hyperactivity disorder
Atomoxetine is a well-tolerated, nonstimulant medication for treating attention-deficit/hyperactivity disorder (ADHD) in children, adolescents, and adults.
Atomoxetine: the first nonstimulant for the management of attention-deficit/hyperactivity disorder.
Atomoxetine is a safe and well-tolerated non-stimulant for ADHD treatment in children, adolescents, and adults, offering an alternative option for those who do not respond to or cannot tolerate stimulants.
DOI